Metalloproteinase-mediated release of human Fas ligand - PubMed (original) (raw)

Metalloproteinase-mediated release of human Fas ligand

N Kayagaki et al. J Exp Med. 1995.

Abstract

Fas ligand (FasL) is a type II integral membrane protein homologous with tumor necrosis factor (TNF). Recent studies indicate that TNF is processed to yield the soluble cytokine by metalloproteinases at the cell surface of activated macrophages and T cells. In the present study, we investigated whether FasL is also released by metalloproteinases. Treatment with hydroxamic acid inhibitors of matrix metalloproteinases specifically led to accumulation of membrane-type FasL (p40) on the surface of human FasL cDNA transfectants and activated human T cells, as estimated by surface immunofluorescence and immunoprecipitation with newly established anti-human FasL monoclonal antibodies. This surface accumulation of mFasL was associated with the decrease of soluble FasL (p27) in the supernatant as estimated by quantitative ELISA and immunoprecipitation with anti-human FasL monoclonal antibodies. These results indicate that human FasL is efficiently released from the cell surface by metalloproteinases like TNF.

PubMed Disclaimer

References

    1. Arthritis Rheum. 1994 Jun;37(6):951-6 - PubMed
    1. Immunol Rev. 1995 Aug;146:223-39 - PubMed
    1. Nature. 1994 Aug 18;370(6490):555-7 - PubMed
    1. Nature. 1994 Aug 18;370(6490):558-61 - PubMed
    1. Int Immunol. 1994 Oct;6(10):1567-74 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources